

Acadia Pharmaceuticals at a Glance

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Rett syndrome and neuropsychiatric symptoms in central nervous system (CNS) disorders.

For more information visit us at Acadia.com or follow us on [LinkedIn](#) and [Twitter](#).



Corporate Milestones

- MAY 2004** ● Acadia completes its initial public offering and trades under the symbol “ACAD” on the Nasdaq Stock Market
- APR 2016** ● FDA approves NUPLAZID® (pimavanserin)
- AUG 2018** ● Acadia enters into exclusive North American license agreement with Neuren Pharmaceuticals Ltd. for the development and commercialization of trofinetide¹
- NOV 2019** ● Acadia announces top-line results from its ADVANCE study evaluating pimavanserin as a potential treatment for the negative symptoms of schizophrenia²
- MAY 2020** ● Acadia and Vanderbilt University announce exclusive license agreement and research collaboration to develop and commercialize novel drug candidates with potential to treat a range of central nervous system disorders
- DEC 2021** ● Acadia announces positive results from its pivotal LAVENDER™ study evaluating trofinetide¹
- JAN 2022** ● Acadia and Stoke Therapeutics establish collaboration to pursue multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases³
- JUL 2022** ● Acadia submits new drug application (NDA) to the FDA for trofinetide¹
- MAR 2023** ● FDA approves DAYBUE™ (trofinetide)¹

¹Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals. ²Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA. ³Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.

Acadia Connect®

Acadia Connect a free support program to help patients navigate insurance approvals, manage costs, and guide patients, caregivers, and their healthcare providers to useful financial resources.

Those enrolled are paired with a dedicated Care Coordinator to offer insurance and prescription assistance. Visit AcadiaConnect.com for more information.

Marketed Products



Please see [full prescribing information](#), including **Boxed WARNING**, also available at Nuplazidhcp.com



Please see [full prescribing information](#) available at Daybue.com¹

Pipeline

Acadia's neuroscience pipeline is focused on high unmet needs in CNS, including a growing focus on CNS rare diseases. Our pipeline spans late to early and preclinical developments.





Late Stage

- Development efforts focused on pimavanserin for the treatment of negative symptoms of schizophrenia²

Early Stage and Preclinical Programs

- Building upon the learnings of previous research in Alzheimer's disease psychosis, Acadia is investing in a wholly-owned new molecule, currently in Phase 1
- Pursuing multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases through collaboration with Stoke Therapeutics³
- Developing a novel approach for improving cognitive function and other neuropsychiatric symptoms in patients with CNS disorders in collaboration with Vanderbilt University

Addressing Significant Unmet Needs in CNS

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Registration
Pimavanserin ²	Negative Symptoms of Schizophrenia					
ACP-204 ⁴	Alzheimer's Disease Psychosis					
ASO Programs ³	SYNGAP1; Rett Syndrome; Undisclosed					
Other Programs	Neuropsychiatric Symptoms					

ASO = Antisense oligonucleotide.

Contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.

¹Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals. ²Safety and efficacy of pimavanserin for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA. ³Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases. ⁴ACP-204 is an investigational agent, and the safety and efficacy of this agent has not been established. There is no guarantee this investigational agent will be filed with or approved by any regulatory agency